Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2025 18:14 ET | Source: Monteverde & Associates PC

HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN

NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- We wish you a Happy Thanksgiving and Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), who has...
November 13, 2025 17:30 ET | Source: Monteverde & Associates PC

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Mersana Therapeutics, Inc. (NASDAQ: MRSN)

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for...
June 23, 2023 16:30 ET | Source: Kaplan Fox & Kilsheimer LLP

Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations

NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc....
June 19, 2023 18:54 ET | Source: Kaplan Fox & Kilsheimer LLP

INVESTOR ALERT: Kaplan Fox Investigates Mersana Therapeutics, Inc. (Nasdaq: MRSN)

NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc....
November 08, 2018 17:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
November 06, 2018 17:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2018 Financial Results and Business Updates

CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
September 26, 2018 16:03 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
September 25, 2018 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Presents New Preclinical Data on XMT-1536 at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer

Novel Immunohistochemistry Assay Distinguishes Non-Small Cell Lung Cancer (NSCLC) Subtypes XMT-1536 Phase 1 Dose Escalation Ongoing With Data Reporting in the First Half of 2019 CAMBRIDGE, Mass.,...
August 14, 2018 16:20 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Second Quarter 2018 Financial Results and Provides Business Updates

Response to the FDA Partial Clinical Hold Submitted This Week Strong Balance Sheet with a cash position of $97M to close Q2 CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Mersana...
August 08, 2018 16:03 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at the Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...